SCHEMBL751142

SCHEMBL751142

C[C@H](NC(=O)[C@@H](N)CCC(=O)O)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.65
DPP9 Q86TI2 3/20 0.65
DPP8 Q6V1X1 2/20 0.65
CYP1A2 P05177 2/20 0.55
GRM8 O00222 1/20 0.55
GRM6 O15303 1/20 0.55
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GSR P00390 1/20 0.55
GRIK1 P39086 1/20 0.55
GRM5 P41594 1/20 0.55
GRIA1 P42261 1/20 0.55
GRIA2 P42262 1/20 0.55
GRIA3 P42263 1/20 0.55
SLC1A3 P43003 1/20 0.55
SLC1A2 P43004 1/20 0.55
SLC1A1 P43005 1/20 0.55
GRIA4 P48058 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27996817 1.00 DPP4 (0.65) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL751143 1.00 DPP4 (0.65) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29415456 1.00 DPP4 (0.65) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL2807373 0.96 DPP4 (0.61) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29569099 0.96 DPP4 (0.61) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL31031060 0.96 DPP4 (0.61) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL30463268 0.92 DPP4 (0.56) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29517333 0.92 DPP4 (0.56) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29375127 0.91 BACE1 (0.60) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29367962 0.91 DPP4 (0.55) DPP4DPP9DPP8CYP1A2GRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118897023-B Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay 中国农业科学院北京畜牧兽医研究所 2025-03-25 CN claimed
US-20250059235-A1 CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME UNIV DREXEL (US) 2025-02-20 US claimed
CN-119104584-A Diagnostic model and application thereof in diagnosis of aortic aneurysm 首都医科大学附属北京友谊医院 2024-12-10 CN claimed
CN-118897023-A Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay 中国农业科学院北京畜牧兽医研究所 2024-11-05 CN claimed
CN-118290518-A Composition containing gamma-aminobutyric acid and active peptide and application of composition in preparation of product with muscle contraction inhibiting activity 深圳海创生物科技有限公司 2024-07-05 CN claimed
CN-117756882-A Preparation method of L-glutamyl-L-alanine 武汉桀升生物科技有限公司 2024-03-26 CN claimed
CN-117304257-A Active peptide, composition and application thereof in preparation of products with antioxidant and/or anti-aging effects 深圳海创生物科技有限公司 2023-12-29 CN claimed
US-20230355708-A1 COMPOSITIONS FOR INHIBITING VIRAL ENTRY AND METHODS USING SAME UNIV DREXEL (US) 2023-11-09 US claimed
CN-116836223-A Prinsepia utilis royle active peptide composition and new application thereof 昆明理工大学 2023-10-03 CN claimed
CN-112852905-B Application of dipeptide in improving paramylon content in euglena 优格天成生物技术(义乌)有限公司 2023-06-23 CN claimed
EP-3310191-A1 SYNERGISTIC BEVERAGE COMPOSITION Chigurupati, Harsha (IN) 2018-04-25 EP claimed
CN-107920577-A Synergistic beverage composition 哈沙·奇古鲁帕蒂 2018-04-17 CN claimed
WO-2017216813-A1 COMPOSITION TO REDUCE DNA AND HEPATIC DAMAGE AND TO ENHANCE REPAIR THEREOF CHIGURUPATI HARSHA (IN) 2017-12-21 WO claimed
US-20170362394-A1 Composition to Reduce DNA and Hepatic Damage and to Enhance Repair Thereof CHIGURUPATI, Harsha (IN) 2017-12-21 US claimed
EP-3257513-A1 COMPOSITION TO REDUCE DNA AND HEPATIC DAMAGE AND TO ENHANCE REPAIR THEREOF Chigurupati, Harsha (IN) 2017-12-20 EP claimed
WO-2016203499-A1 SYNERGISTIC BEVERAGE COMPOSITION CHIGURUPATI HARSHA (IN) 2016-12-22 WO claimed
US-20160367478-A1 Synergistic Beverage Composition CHIGURUPATI, Harsha (IN) 2016-12-22 US claimed
WO-2016196743-A1 METHODS AND SYSTEMS FOR DETECTING MELANOMA THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-12-08 WO claimed
EP-2640423-A1 LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY Ischemix LLC (US) 2013-09-25 EP claimed
WO-2012067947-A1 LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY ISCHEMIX LLC (US) 2012-05-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059235-A1 CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME ZC3HAV1, VIP, LNPEP DPP4 44/4885DPP9 62/4885DPP8 75/4885
US-20230355708-A1 COMPOSITIONS FOR INHIBITING VIRAL ENTRY AND METHODS USING SAME GALNT1, GALNT2, LGALS1 DPP4 1264/4885DPP9 1525/4885DPP8 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.